HH268

HH268 is a bispecific monoclonal antibody currently in development by Huahui Health for the treatment of hematologic malignancies. As a bispecific antibody, it is engineered to bind to two different antigens or epitopes simultaneously, a strategy often used in oncology to bridge immune effector cells to tumor cells or to inhibit multiple signaling pathways. HH268 is part of Huahui Health's oncology portfolio, which leverages the company's expertise in antibody engineering. Detailed information regarding its specific molecular targets and clinical trial status has not yet been publicly disclosed, but it is positioned as a candidate for various blood-borne cancers.